Pfizer's COVID Drug Data Supports Use in High-Risk Patients:

The US health regulator's staff reviewers said on Tuesday data from Pfizer's COVID-19 drug trials support its use in adults at high risk of progressing to severe disease, bringing the pill closer to a full approval.

Related Keywords

Boston , Massachusetts , United States , Bengaluru , Karnataka , India , Shailesh Kuber , Khushi Mandowara , Shinjini Ganguli , Leroy Leo , Anthony Fauci , Joe Biden , Scott Dryden Peterson , Pfizer , Pfizer Inc , National Institute Of Allergy , Drug Administration , Reuters , President Joe Biden , National Institute , Infectious Diseases , Mass General Brigham , Covid 19 Treatment , Covid 19 , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Corona Virus , Ovid19 , Ovel Coronavirus Sars Cov 2 ,